111 related articles for article (PubMed ID: 23423940)
1. [Kinases and phosphatases: key enzymes in targeted cancer therapy].
Schulze M; Gohla A
Dtsch Med Wochenschr; 2013 Mar; 138(9):437-40. PubMed ID: 23423940
[No Abstract] [Full Text] [Related]
2. Phosphatases: Their Roles in Cancer and Their Chemical Modulators.
Fontanillo M; Köhn M
Adv Exp Med Biol; 2016; 917():209-40. PubMed ID: 27236558
[TBL] [Abstract][Full Text] [Related]
3. Rising of phosphatases as targets of cancer treatment.
Heneberg P
Anticancer Agents Med Chem; 2011 Jan; 11(1):1-3. PubMed ID: 21395544
[No Abstract] [Full Text] [Related]
4. Protein kinases and phosphatases as therapeutic targets in cancer.
Ventura JJ; Nebreda AR
Clin Transl Oncol; 2006 Mar; 8(3):153-60. PubMed ID: 16648114
[TBL] [Abstract][Full Text] [Related]
5. The hMTH1 paradox: antioxidants recommended in cancer?
Sanchis-Gomar F; Pareja-Galeano H; Lucía A
DNA Repair (Amst); 2014 Sep; 21():163-4. PubMed ID: 24802094
[No Abstract] [Full Text] [Related]
6. Cancer: Damage prevention targeted.
Dominissini D; He C
Nature; 2014 Apr; 508(7495):191-2. PubMed ID: 24695227
[No Abstract] [Full Text] [Related]
7. Cancer therapy. Targeting the poison within.
Smits VA; Gillespie DA
Cell Cycle; 2014; 13(15):2330-3. PubMed ID: 25483183
[TBL] [Abstract][Full Text] [Related]
8. Protein kinases as targets for cancer treatment.
Giamas G; Stebbing J; Vorgias CE; Knippschild U
Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
[TBL] [Abstract][Full Text] [Related]
9. Kinase overexpressing cancers responsive to drug withdrawal.
Amin AD; Rajan SS; Schatz JH
Aging (Albany NY); 2015 Oct; 7(10):752-3. PubMed ID: 26525633
[No Abstract] [Full Text] [Related]
10. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).
Ardito F; Giuliani M; Perrone D; Troiano G; Lo Muzio L
Int J Mol Med; 2017 Aug; 40(2):271-280. PubMed ID: 28656226
[TBL] [Abstract][Full Text] [Related]
11. Ectokinases as novel cancer markers and drug targets in cancer therapy.
Yalak G; Vogel V
Cancer Med; 2015 Mar; 4(3):404-14. PubMed ID: 25504773
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of protein kinases and phosphatases.
MacKintosh C; MacKintosh RW
Trends Biochem Sci; 1994 Nov; 19(11):444-8. PubMed ID: 7855884
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibitors beyond monotherapy: current and future development.
Templeton IE; Musib L
Curr Opin Pharmacol; 2015 Aug; 23():61-7. PubMed ID: 26057212
[TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapy: when to stop and when to continue?
Hirsch FR; Mok TS; Borges V; Bunn PA
Lancet Oncol; 2010 Aug; 11(8):709-11. PubMed ID: 20570560
[No Abstract] [Full Text] [Related]
15. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
16. The druggability of intracellular nucleotide-degrading enzymes.
Rampazzo C; Tozzi MG; Dumontet C; Jordheim LP
Cancer Chemother Pharmacol; 2016 May; 77(5):883-93. PubMed ID: 26614508
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation, Signaling, and Cancer: Targets and Targeting.
Marmiroli S; Fabbro D; Miyata Y; Pierobon M; Ruzzene M
Biomed Res Int; 2015; 2015():601543. PubMed ID: 26576427
[No Abstract] [Full Text] [Related]
18. A comprehensive review of protein kinase inhibitors for cancer therapy.
Kannaiyan R; Mahadevan D
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1249-1270. PubMed ID: 30259761
[TBL] [Abstract][Full Text] [Related]
19. BRAF inhibitors: the current and the future.
Zhang W
Curr Opin Pharmacol; 2015 Aug; 23():68-73. PubMed ID: 26072431
[TBL] [Abstract][Full Text] [Related]
20. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
